Drug Index

Eteplirsen

 
print

Mechanism :

Binds to exon 51 of dystrophin pre-messenger RNA (mRNA), resulting in exclusion of this exon during mRNA processing. Exon skipping allows for production of an internally truncated dystrophin protein.


Indication :

• Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.


Contraindications :

No contraindications.


Dosing :

Male children ≥7 years: IV 30 mg/kg/dose once weekly.


Adverse Effect :

Equilibrium disturbance, contact dermatitis, vomiting, bronchospasm, cough, dyspnea.


Interaction :

No known significant interactions.


07/15/2019 05:51:04 Eteplirsen
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0